New and experimental skin-directed therapies for cutaneous lymphomas

Arpad Farkas, Lajos Kemeny, Lars E. French, Reinhard Dummer

Research output: Contribution to journalReview article

19 Citations (Scopus)


Primary cutaneous lymphomas (CLs) originate in the skin and should be differentiated from secondary skin infiltrates, which are manifestations of lymphomas of nodal or extranodal origin. These rare diseases include various lymphoproliferative disorders: cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and some rare subtypes. As definitive cure is often not possible, it is important to control the disease and alleviate symptoms. Patients with early-stage disease limited to the skin usually require skin-directed therapies using topical agents including corticosteroids, chemotherapeutic drugs, bexarotene gel, electron beam therapy and phototherapy. Each of these are effective; however, all have some disadvantages and are associated with significant adverse events. In the field of skin-directed therapies there are interesting developments using antineoplastic compounds, the retinoid tazarotene, imiquimod, gene therapy products (adenovirus vector expressing γ-interferon), the monoclonal anti-CD20 antibody rituximab, photodynamic therapy and 308-nm excimer laser to mention a few. This review highlights some of the promising new and experimental local therapies for primary CLs and focuses on their efficacy and side effects.

Original languageEnglish
Pages (from-to)322-334
Number of pages13
JournalSkin Pharmacology and Physiology
Issue number6
Publication statusPublished - Nov 1 2009


  • 308-nm excimer laser
  • Cutaneous lymphoma
  • Hexadecylphosphocholine
  • Imiquimod
  • Methotrexate
  • Photodynamic therapy
  • Rituximab
  • Skin-directed therapy
  • TG-1042
  • Tazarotene

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Dermatology

Fingerprint Dive into the research topics of 'New and experimental skin-directed therapies for cutaneous lymphomas'. Together they form a unique fingerprint.

  • Cite this